ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012;Guia de practica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012: Grupo de Trabajo de Diagnóstico y Tratamiento de la Insuficiencia Cardiaca Aguda y Cronica 2012 de la Sociedad Europea de Cardiologia. Elaborada en colaboracion con la Asociacion de Insuficiencia Cardiaca (ICA) de la ESC

Revista Espanola de Cardiologia

Volumn 65, Issue 10, 2012, Pages

  McMurray, John J V ^a   Adamopoulos, Stamatis ^b   Anker, Stefan D ^b   Auricchio, Angelo ^b   Böhm, Michael ^b   Dickstein, Kenneth ^b   Falk, Volkmar ^b   Filippatos, Gerasimos ^b   Fonseca, Cândida ^b   Gomez Sanchez, Miguel Angel ^b   Jaarsma, Tiny ^b   Kober, Lars ^b   Lip, Gregory Y H ^a   Maggioni, Aldo Pietro ^b   Parkhomenko, Alexander ^b   Pieske, Burkert M ^b   Popescu, Bogdan A ^b   Ronnevik, Per K ^b   Rutten, Frans H ^b   Schwitter, Juerg ^b   Seferovic, Petar ^b   Stepinska, Janina ^b   Trindade, Pedro T ^b   Voors, Adriaan A ^b   Zannad, Faiez ^b   Zeiher, Andreas ^b   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NONE

Author keywords

Bloqueadores beta; Bloqueadores del sistema renina angiotensina; Digital; Fracci n de eyecci n; Insuficiencia cardiaca; P ptidos natriur ticos; Trasplante

Indexed keywords

ARTICLE; HEART FAILURE; PRACTICE GUIDELINE;

EID: 84866913885     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2012.08.003     Document Type: Article

References (271)

1. K. Dickstein, A. Cohen-Solal, G. Filippatos, J.J. McMurray, P. Ponikowski, P.A. Poole-Wilson, A. Stromberg, D.J. van Veldhuisen, D. Atar, A.W. Hoes, A. Keren, A. Mebazaa, M. Nieminen, S.G. Priori, and K. Swedberg ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail. 10 2008 933 989
2. A.P. Davie, C.M. Francis, L. Caruana, G.R. Sutherland, and J.J. McMurray Assessing diagnosis in heart failure: which features are any use? QJM 90 1997 335 339
3. MantJ, DoustJ, Roalfe A, Barton R Cowie MR, Glasziou R Mant D, McManus RJ, Holder R, Deeks J, Fletcher K, Qume M, Sohanpal S, Sanders S, Hobbs FD. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009; 13:1-207, iii.
4. I. Oudejans, A. Mosterd, J.A. Bloemen, M.J. Valk, E. van Velzen, J.P. Wielders, N.P. Zuithoff, F.H. Rutten, and A.W. Hoes Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests Eur J Heart Fail. 13 2011 518 527
5. C. Fonseca Diagnosis of heart failure in primary care Heart Fail Rev. 11 2006 95 107
6. J.C. Kelder, M.J. Cramer, J. van Wijngaarden, R. van Tooren, A. Mosterd, K.G. Moons, J.W. Lammers, M.R. Cowie, D.E. Grobbee, and A.W. Hoes The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure Circulation. 124 2011 2865 2873
7. B.A. Borlaug, and W.J. Paulus Heart failure with preserved ejection fraction: pathophysiology diagnosis treatment Eur Heart J. 32 2011 670 679
8. W.J. Paulus, C. Tschope, J.E. Sanderson, C. Rusconi, F.A. Flachskampf, F.E. Rademakers, P. Marino, O.A. Smiseth, G. De Keulenaer, A.F. Leite-Moreira, A. Borbely, I. Edes, M.L. Handoko, S. Heymans, N. Pezzali, B. Pieske, K. Dickstein, A.G. Fraser, and D.L. Brutsaert How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology Eur Heart J. 28 2007 2539 2550
9. T.H. Marwick, S.V. Raman, I. Carrio, and J.J. Bax Recent developments in heart failure imaging JACC Cardiovasc Imaging. 3 2010 429 439
10. D.I. Paterson, E. O'Meara, B.J. Chow, H. Ukkonen, and R.S. Beanlands Recent advances in cardiac imaging for patients with heart failure Curr Opin Cardiol 26 2011 132 143
11. J.J. McMurray Clinical practice Systolic heart failure N Engl J Med. 362 2010 228 238
12. J. Chen, S.L. Normand, Y. Wang, and H.M. Krumholz National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008 JAMA. 306 2011 1669 1678
13. S.M. Dunlay, M.M. Redfield, S.A. Weston, T.M. Therneau, K. Hall Long, N.D. Shah, and V.L. Roger Hospitalizations after heart failure diagnosis a community perspective J Am Coll Cardiol. 54 2009 1695 1702
14. U.N. Khot, G. Jia, D.J. Moliterno, A.M. Lincoff, M.B. Khot, R.A. Harrington, and E.J. Topol Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification JAMA. 290 2003 2174 2181
15. A. Mosterd, and A.W. Hoes Clinical epidemiology of heart failure Heart. 93 2007 1137 1146
16. M.J. Ackerman, S.G. Priori, S. Willems, C. Berul, R. Brugada, H. Calkins, A.J. Camm, P.T. Ellinor, M. Gollob, R. Hamilton, R.E. Hershberger, D.P. Judge, H. Le Marec, W.J. McKenna, E. Schulze-Bahr, C. Semsarian, J.A. Towbin, H. Watkins, A. Wilde, C. Wolpert, and D.P. Zipes HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA) Heart Rhythm. 8 2011 1308 1339
17. K. Hogg, K. Swedberg, and J. McMurray Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis J Am Coll Cardiol. 43 2004 317 327
18. C.S. Lam, E. Donal, E. Kraigher-Krainer, and R.S. Vasan Epidemiology and clinical course of heart failure with preserved ejection fraction Eur J Heart Fail. 13 2011 18 28
19. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. doi: 10.1093/eurheartj/ehr254. Published online ahead of print 6 August 2011.
20. A.M. Shah, and D.L. Mann In search of new therapeutic targets and strategies for heart failure: recent advances in basic science Lancet. 378 2011 704 712
21. S. Stewart, K. MacIntyre, D.J. Hole, S. Capewell, and J.J. McMurray More 'malignant' than cancer? Five-year survival following a first admission for heart failure Eur J Heart Fail. 3 2001 315 322
22. S. Stewart, I. Ekman, T. Ekman, A. Oden, and A. Rosengren Population impact of heart failure and the most common forms of cancer: a study of 1162 309 hospital cases in Sweden (1988 to 2004) Circ Cardiovasc Qual Outcomes. 3 2010 573 580
23. P.S. Jhund, K. Macintyre, C.R. Simpson, J.D. Lewsey, S. Stewart, A. Redpath, J.W. Chalmers, S. Capewell, and J.J. McMurray Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people Circulation. 119 2009 515 523
24. F.H. Rutten, K.G. Moons, M.J. Cramer, D.E. Grobbee, N.P. Zuithoff, J.W. Lammers, and A.W. Hoes Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study BMJ. 331 2005 1379
25. N.M. Hawkins, M.C. Petrie, P.S. Jhund, G.W. Chalmers, F.G. Dunn, and J.J. McMurray Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology Eur J Heart Fail. 11 2009 130 139
26. L.B. Daniels, P. Clopton, V. Bhalla, R. Krishnaswamy, R.M. Nowak, J. McCord, J.E. Hollander, P. Duc, T. Omland, A.B. Storrow, W.T. Abraham, A.H. Wu, P.G. Steg, A. Westheim, C.W. Knudsen, A. Perez, R. Kazanegra, H.C. Herrmann, P.A. McCullough, and A.S. Maisel How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study Am Heart J. 151 2006 999 1005
27. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010; 23:685-713; quiz 786-688.
28. H. Dokainish, J.S. Nguyen, J. Bobek, R. Goswami, and N.M. Lakkis Assessment of the American Society of Echocardiography-European Association of Echocardiography guidelines for diastolic function in patients with depressed ejection fraction: an echocardiographic and invasive haemodynamic study Eur J Echocardiogr. 12 2011 857 864
29. KirkpatrickJN, M.A. Vannan, J. Narula, and R.M. Lang Echocardiography in heart failure: applications, utility, and new horizons J Am Coll Cardiol. 50 2007 381 396
30. R. Lancellotti, L. Moura, L.A. Pierard, E. Agricola, B.A. Popescu, C. Tribouilloy, A. Hagendorff, J.L. Monin, L. Badano, and J.L. Zamorano European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease) Eur J Echocardiogr. 11 2010 307 332
31. P. Lancellotti, C. Tribouilloy, A. Hagendorff, L. Moura, B.A. Popescu, E. Agricola, J.L. Monin, L.A. Pierard, L. Badano, and J.L. Zamorano European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease) Eur J Echocardiogr. 11 2010 223 244
32. B.A. Popescu, M.J. Andrade, L.P. Badano, K.F. Fox, F.A. Flachskampf, P. Lancellotti, A. Varga, R. Sicari, A. Evangelista, P. Nihoyannopoulos, J.L. Zamorano, G. Derumeaux, J.D. Kasprzak, and J.R. Roelandt European Association of Echocardiography recommendations for training, competence, and quality improvement in echocardiography Eur J Echocardiogr. 10 2009 893 905
33. S.F. Nagueh, R. Bhatt, R.P. Vivo, S.R. Krim, S.I. Sarvari, K. Russell, T. Edvardsen, O.A. Smiseth, and J.D. Estep Echocardiographic evaluation of hemodynamics in patients with decompensated systolic heart failure Circ Cardiovasc Imaging. 4 2011 220 227
34. R. Sicari, P. Nihoyannopoulos, A. Evangelista, J. Kasprzak, R. Lancellotti, D. Poldermans, J.U. Voigt, and J.L. Zamorano Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC) Eur J Echocardiogr. 9 2008 415 437
35. A.P. Davie, C.M. Francis, M.P. Love, L. Caruana, I.R. Starkey, T.R. Shaw, G.R. Sutherland, and J.J. McMurray Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction BMJ. 312 1996 222
36. J.T. Thomas, R.F. Kelly, S.J. Thomas, T.D. Stamos, K. Albasha, J.E. Parrillo, and J.E. Calvin Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure Am J Med. 112 2002 437 445
37. K. Khunti, I. Squire, K.R. Abrams, and A.J. Sutton Accuracy of a 12-lead electrocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta-analysis Eur J Heart Fail. 6 2004 571 576
38. J.E. Madias Why recording of an electrocardiogram should be required in every inpatient and outpatient encounter of patients with heart failure Pacing Clin Electrophysiol. 34 2011 963 967
39. B. Ewald, D. Ewald, A. Thakkinstian, and J. Attia Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction Intern Med J. 38 2008 101 113
40. J.A. Doust, P.P. Glasziou, E. Pietrzak, and A.J. Dobson A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure Arch Intern Med. 164 2004 1978 1984
41. A. Zaphiriou, S. Robb, T. Murray-Thomas, G. Mendez, K. Fox, T. McDonagh, S.M. Hardman, H.J. Dargie, and M.R. Cowie The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study Eur J Heart Fail. 7 2005 537 541
42. A. Maisel, C. Mueller, K. Adams Jr., S.D. Anker, N. Aspromonte, J.G. Cleland, A. Cohen-Solal, U. Dahlstrom, A. DeMaria, S. Di Somma, G.S. Filippatos, G.C. Fonarow, R. Jourdain, M. Komajda, P.P. Liu, T. McDonagh, K. McDonald, A. Mebazaa, M.S. Nieminen, W.F. Peacock, M. Tubaro, R. Valle, M. Vanderhyden, C.W. Yancy, F. Zannad, and E. Braunwald State of the art: using natriuretic peptide levels in clinical practice Eur J Heart Fail. 10 2008 824 839
43. A. Fuat, J.J. Murphy, A.P. Hungin, J. Curry, A.A. Mehrzad, A. Hetherington, J.I. Johnston, W.S. Smellie, V. Duffy, and P. Cawley The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure Br J Gen Pract. 56 2006 327 333
44. K. Yamamoto, J.C. Burnett Jr., E.A. Bermudez, M. Jougasaki, K.R. Bailey, and M.M. Redfield Clinical criteria and biochemical markers for the detection of systolic dysfunction J Card Fail. 6 2000 194 200
45. M.R. Cowie, A.D. Struthers, D.A. Wood, A.J. Coats, S.G. Thompson, P.A. Poole-Wilson, and G.C. Sutton Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care Lancet. 350 1997 1349 1353
46. P. Krishnaswamy, E. Lubien, P. Clopton, J. Koon, R. Kazanegra, E. Wanner, N. Gardetto, A. Garcia, A. DeMaria, and A.S. Maisel Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction AmJ Med. 111 2001 274 279
47. J.C. Kelder, M.R. Cowie, T.A. McDonagh, S.M. Hardman, D.E. Grobbee, B. Cost, and A.W. Hoes Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis Heart. 97 2011 959 963
48. J.C. Kelder, M.J. Cramer, W.M. Verweij, D.E. Grobbee, and A.W. Hoes Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure J Card Fail. 17 2011 729 734
49. F. Gustafsson, F. Steensgaard-Hansen, BadskjaerJ, A.H. Poulsen, R. Corell, and P. Hildebrandt Diagnostic and prognostic performance of N-terminal proBNP in primary care patients with suspected heart failure J Card Fail. 11 2005 S15 S20
50. O.W. Nielsen, V. Rasmussen, N.J. Christensen, and J.F. Hansen Neuroendocrine testing in community patients with heart disease: plasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability Scand J Clin Lab Invest. 64 2004 619 628
51. A. Maisel, C. Mueller, R. Nowak, W.F. Peacock, J.W. Landsberg, P. Ponikowski, M. Mockel, C. Hogan, A.H. Wu, M. Richards, R. Clopton, G.S. Filippatos, S. Di Somma, I. Anand, L. Ng, L.B. Daniels, S.X. Neath, R. Christenson, M. Potocki, J. McCord, G. Terracciano, D. Kremastinos, O. Hartmann, S. von Haehling, A. Bergmann, N.G. Morgenthaler, and S.D. Anker Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial J Am Coll Cardiol. 55 2010 2062 2076
52. J. Schwitter Extending the frontiers of cardiac magnetic resonance Circulation. 118 2008 109 112
53. R. Gebker, J. Schwitter, E. Fleck, and E. Nagel How we perform myocardial perfusion with cardiovascular magnetic resonance J Cardiovasc Magn Reson. 9 2007 539 547
54. G.A. Beller, and R.C. Heede SPECT imaging for detecting coronary artery disease and determining prognosis by noninvasive assessment of myocardial perfusion and myocardial viability J Cardiovasc Transl Res. 4 2011 416 424
55. D.P. Leong, C.G. De Pasquale, and J.B. Selvanayagam Heart failure with normal ejection fraction: the complementary roles of echocardiography and CMR imaging JACC Cardiovasc Imaging. 3 2010 409 420
56. Myerson SG. Valvular and hemodynamic assessment with CMR. Heart Fail Clin. 2009; 5:389-400, vi-vii.
57. Raman SV, Simonetti OP. The CMR examination in heart failure. Heart Fail Clin. 2009; 5:283-300, v.
58. Y. Sheikine, and M.F. Di Carli Integrated PET/CT in the assessment of etiology and viability in ischemic heart failure Curr Heart Fail Rep. 5 2008 136 142
59. J.M. Miller, C.E. Rochitte, M. Dewey, A. Arbab-Zadeh, H. Niinuma, I. Gottlieb, N. Paul, M.E. Clouse, E.P. Shapiro, J. Hoe, A.C. Lardo, D.E. Bush, A. de Roos, C. Cox, J. Brinker, and J.A. Lima Diagnostic performance of coronary angiography by 64-row CT N Engl J Med. 359 2008 2324 2336
60. R.S. Beanlands, G. Nichol, E. Huszti, D. Humen, N. Racine, M. Freeman, K.Y. Gulenchyn, L. Garrard, R. deKemp, A. Guo, T.D. Ruddy, F. Benard, A. Lamy, and R.M. Iwanochko F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2) J Am Coll Cardiol. 50 2007 2002 2012
61. R.M. Lang, M. Bierig, R.B. Devereux, F.A. Flachskampf, E. Foster, P.A. Pellikka, M.H. Picard, M.J. Roman, J. Seward, ShanewiseJ, S. Solomon, K.T. Spencer, M. St John Sutton, and W. Stewart Recommendations for chamber quantification Eur J Echocardiogr. 7 2006 79 108
62. R.M. Lang, L.P. Badano, W. Tsang, D.H. Adams, E. Agricola, T. Buck, F.F. Faletra, A. Franke, HungJ, L.P. de Isla, O. Kamp, KasprzakJD, R. Lancellotti, MarwickTH, M.L. McCulloch, M.J. Monaghan, P. Nihoyannopoulos, N.G. Pandian, P.A. Pellikka, M. Pepi, D.A. Roberson, S.K. Shernan, G.S. Shirali, L. Sugeng, F.J. Ten Cate, M.A. Vannan, J.L. Zamorano, and W.A. Zoghbi EAE/ASE Recommendations for Image Acquisition and Display Using Three-Dimensional Echocardiography Eur Heart J Cardiovasc Imaging. 13 2012 1 46
63. S.F. Nagueh, C.P. Appleton, T.C. Gillebert, P.N. Marino, J.K. Oh, O.A. Smiseth, A.D. Waggoner, F.A. Flachskampf, P.A. Pellikka, and A. Evangelisa Recommendations for the evaluation of left ventricular diastolic function by echocardiography Eur J Echocardiogr. 10 2009 165 193
64. S.F. Nagueh, K.J. Middleton, H.A. Kopelen, W.A. Zoghbi, and M.A. Quinones Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures J Am Coll Cardiol. 30 1997 1527 1533
65. J. Schwitter, and A.E. Arai Assessment of cardiac ischaemia and viability: role of cardiovascular magnetic resonance Eur Heart J 32 2011 799 809
66. P.J. Kilner, T. Geva, H. Kaemmerer, P.T. Trindade, J. Schwitter, and G.D. Webb Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology Eur Heart J. 31 2010 794 805
67. Luchinger R, Schwitter J, Bruder O. Safety of CMR. En: Schwitter J, ed. CMR Update 2012. 2nd ed. Lausanne; p. 31-51. ISBN: 978-3-033-01674-3.
68. O. Bruder, S. Schneider, D. Nothnagel, G. Pilz, M. Lombardi, A. Sinha, A. Wagner, T. Dill, H. Frank, A. van Rossum, J. Schwitter, E. Nagel, J. Senges, G. Sabin, U. Sechtem, and H. Mahrholdt Acute adverse reactions to gadolinium-based contrast agents in CMR: multicenter experience with 17,767 patients. from the EuroCMR Registry J Am Coll Cardiol-Cardiovasc Imaging. 4 2011 1171 1176
69. Y. Sheikine, and M.F. Di Carli Integrated PET/CT in the assessment of etiology and viability in ischemic heart failure Curr Heart Fail Rep. 5 2008 136 142
70. P.A. Tonino, B. De Bruyne, N.H. Pijls, U. Siebert, F. Ikeno, M. van' t Veer, V. Klauss, G. Manoharan, T. Engstrom, K.G. Oldroyd, P.N. Ver Lee, P.A. MacCarthy, and W.F. Fearon Fractional flow reserve versus angiography for guiding percutaneous coronary intervention N Engl J Med. 360 2009 213 224
71. W. Wijns, R. Kolh, N. Danchin, C. Di Mario, V. Falk, T. Folliguet, S. Garg, K. Huber, S. James, KnuutiJ, J. Lopez-Sendon, J. Marco, L. Menicanti, M. Ostojic, M.F. Piepoli, C. Pirlet, PomarJL, N. Reifart, F.L. Ribichini, M.J. Schalij, P. Sergeant, P.W. Serruys, SilberS, M. Sousa Uva, and D. Taggart Guidelines on myocardial revascularization Eur Heart J. 31 2010 2501 2555
72. L.T. Cooper, K.L. Baughman, A.M. Feldman, A. Frustaci, M. Jessup, U. Kuhl, G.N. Levine, J. Narula, R.C. Starling, J. Towbin, and R. Virmani The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology Eur Heart J. 28 2007 3076 3093
73. R. Arena, MyersJ, and M. Guazzi Cardiopulmonary exercise testing is a core assessment for patients with heart failure Congest Heart Fail. 17 2011 115 119
74. H. Wedel, McMurrayJJ, M. Lindberg, WikstrandJ, ClelandJG, CornelJH, R. Dunselman, A. Hjalmarson, J. Kjekshus, M. Komajda, T. Kuusi, J. Vanhaecke, and F. Waagstein Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide Eur J Heart Fail. 11 2009 281 291
75. L.A. Allen, G.M. Felker, S. Pocock, J.J. McMurray, M.A. Pfeffer, K. Swedberg, D. Wang, S. Yusuf, E.L. Michelson, and C.B. Granger Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program Eur J Heart Fail. 11 2009 170 177
76. C.E. Jackson, S.D. Solomon, H.C. Gerstein, S. Zetterstrand, B. Olofsson, E.L. Michelson, C.B. Granger, K. Swedberg, M.A. Pfeffer, S. Yusuf, and J.J. McMurray Albuminuria in chronic heart failure: prevalence and prognostic importance Lancet. 374 2009 543 550
77. G.M. Felker, L.A. Allen, S.J. Pocock, L.K. Shaw, J.J. McMurray, M.A. Pfeffer, K. Swedberg, D. Wang, S. Yusuf, E.L. Michelson, and C.B. Granger Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank J Am Coll Cardiol. 50 2007 40 47
78. S.J. Pocock, D. Wang, M.A. Pfeffer, S. Yusuf, J.J. McMurray, K.B. Swedberg, J. Ostergren, E.L. Michelson, K.S. Pieper, and C.B. Granger Predictors of mortality and morbidity in patients with chronic heart failure Eur Heart J. 27 2006 65 75
79. M. Komajda, P.E. Carson, S. Hetzel, R. McKelvie, J. McMurray, A. Ptaszynska, M.R. Zile, D. Demets, and B.M. Massie Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE) Circ Heart Fail. 4 2011 27 35
80. E.S. Ketchum, and W.C. Levy Establishing prognosis in heart failure: a multimarker approach Prog Cardiovasc Dis. 54 2011 86 96
81. S. Stewart, A. Jenkins, S. Buchan, A. McGuire, S. Capewell, and J.J. McMurray The current cost of heart failure to the National Health Service in the UK Eur J Heart Fail. 4 2002 361 371
82. S. Masson, R. Latini, I.S. Anand, S. Barlera, L. Angelici, T. Vago, G. Tognoni, and J.N. Cohn Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial) J Am Coll Cardiol. 52 2008 997 1003
83. M. Wong, L. Staszewsky, R. Latini, S. Barlera, A. Volpi, Y.T. Chiang, R.L. Benza, S.O. Gottlieb, T.D. Kleemann, F. Rosconi, P.M. Vandervoort, and J.N. Cohn Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study J Am Coll Cardiol. 40 2002 970 975
84. I. Ekman, J.G. Cleland, B. Andersson, and K. Swedberg Exploring symptoms in chronic heart failure Eur J Heart Fail. 7 2005 699 703
85. M. Packer, K.A. Narahara, U. Elkayam, J.M. Sullivan, D.L. Pearle, B.M. Massie, and M.A. Creager Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study J Am Coll Cardiol. 22 1993 65 72
86. A.J. Cowley, K. Stainer, R.D. Wynne, J.M. Rowley, and J.R. Hampton Comparison of the effects of captopril and enoximone in patients with severe heart failure: a placebo controlled double-blind study Int J Cardiol. 24 1989 311 316
87. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316:1429-35.
88. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302.
89. R. Garg, and S. Yusuf Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials JAMA. 273 1995 1450 1456
90. M. Packer, P.A. Poole-Wilson, P.W. Armstrong, J.G. Cleland, J.D. Horowitz, B.M. Massie, L. Ryden, K. Thygesen, and B.F. Uretsky Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group Circulation. 100 1999 2312 2318
91. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-691.
92. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
93. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353:2001-7.
94. A. Hjalmarson, S. Goldstein, B. Fagerberg, H. Wedel, F. Waagstein, J. Kjekshus, J. Wikstrand, D. El Allaf, J. Vitovec, J. Aldershvile, M. Halinen, R. Dietz, K.L. Neuhaus, A. Janosi, G. Thorgeirsson, P.H. Dunselman, L. Gullestad, J. Kuch, J. Herlitz, P. Rickenbacher, S. Ball, S. Gottlieb, and P. Deedwania Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group JAMA. 283 2000 1295 1302
95. M. Packer, A.J. Coats, M.B. Fowler, H.A. Katus, H. Krum, R. Mohacsi, J.L. Rouleau, M. Tendera, A. Castaigne, E.B. Roecker, M.K. Schultz, and D.L. DeMets Effect of carvedilol on survival in severe chronic heart failure N Engl J Med. 344 2001 1651 1658
96. M. Packer, M.B. Fowler, E.B. Roecker, A.J. Coats, H.A. Katus, H. Krum, P. Mohacsi, J.L. Rouleau, M. Tendera, C. Staiger, T.L. Holcslaw, I. Amann-Zalan, and D.L. DeMets Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study Circulation. 106 2002 2194 2199
97. M.D. Flather, M.C. Shibata, A.J. Coats, D.J. Van Veldhuisen, A. Parkhomenko, J. Borbola, A. Cohen-Solal, D. Dumitrascu, R. Ferrari, P. Lechat, J. Soler-Soler, L. Tavazzi, L. Spinarova, J. Toman, M. Bohm, S.D. Anker, S.G. Thompson, and P.A. Poole-Wilson Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J. 26 2005 215 225
98. M. Packer, M.R. Bristow, J.N. Cohn, W.S. Colucci, M.B. Fowler, E.M. Gilbert, and N.H. Shusterman The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group N Engl J Med. 334 1996 1349 1355
99. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, A. Perez, J. Palensky, and J. Wittes The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med. 341 1999 709 717
100. F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, S.J. Pocock, and B. Pitt Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med. 364 2011 11 21
101. M.D. Flather, S. Yusuf, L. Kober, M. Pfeffer, A. Hall, G. Murray, C. Torp-Pedersen, S. Ball, J. Pogue, L. Moye, and E. Braunwald Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group Lancet. 355 2000 1575 1581
102. J. McMurray, A. Cohen-Solal, R. Dietz, E. Eichhorn, L. Erhardt, F.D. Hobbs, H. Krum, A. Maggioni, R.S. McKelvie, I.L. Pina, J. Soler-Soler, and K. Swedberg Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice Eur J Heart Fail. 7 2005 710 721
103. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001; 344:1659-67.
104. P.A. Poole-Wilson, K. Swedberg, J.G. Cleland, A. Di Lenarda, P. Hanrath, M. Komajda, J. Lubsen, B. Lutiger, M. Metra, W.J. Remme, C. Torp-Pedersen, A. Scherhag, and A. Skene Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial Lancet. 362 2003 7 13
105. H. Krum, E.B. Roecker, P. Mohacsi, J.L. Rouleau, M. Tendera, A.J. Coats, H.A. Katus, M.B. Fowler, and M. Packer Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study JAMA. 289 2003 712 718
106. G. Jondeau, Y. Neuder, J.C. Eicher, P. Jourdain, E. Fauveau, M. Galinier, A. Jegou, F. Bauer, J.N. Trochu, A. Bouzamondo, M.L. Tanguy, and P. Lechat B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode Eur Heart J. 30 2009 2186 2192
107. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, KleimanJ, and M. Gatlin Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J. Med 348 2003 1309 1321
108. C.B. Granger, J.J. McMurray, S. Yusuf, P. Held, E.L. Michelson, B. Olofsson, J. Ostergren, M.A. Pfeffer, and K. Swedberg Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet. 362 2003 772 776
109. A.P. Maggioni, I. Anand, S.O. Gottlieb, R. Latini, G. Tognoni, and J.N. Cohn Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors J Am Coll Cardiol. 40 2002 1414 1421
110. J.N. Cohn, and G. Tognoni A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med. 345 2001 1667 1675
111. J.J. McMurray, J. Ostergren, K. Swedberg, C.B. Granger, P. Held, E.L. Michelson, B. Olofsson, S. Yusuf, and M.A. Pfeffer Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet. 362 2003 767 771
112. K. Swedberg, M. Komajda, M. Bohm, J.S. Borer, I. Ford, A. Dubost-Brama, G. Lerebours, and L. Tavazzi Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet. 376 2010 875 885
113. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997;336:525-33.
114. J.N. Cohn, D.G. Archibald, S. Ziesche, FranciosaJA, W.E. Harston, F.E. Tristani, W.B. Dunkman, JacobsW, G.S. Francis, and K.H. Flohr for the Veterans Administration Cooperative Study Group. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study N EnglJ Med. 314 1986 1547 1552
115. J.N. Cohn, G. Johnson, S. Ziesche, F. Cobb, G. Francis, F. Tristani, R. Smith, W.B. Dunkman, H. Loeb, M. Wong, G. Bhat, S. Goldman, R.D. Fletcher, J. Doherty, C.V. Hughes, R. Carson, G. Cintron, R. Shabetai, and C. Haakenson A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure N EnglJ Med. 325 1991 303 310
116. A.L. Taylor, S. Ziesche, C. Yancy, P. Carson, R. D'Agostino Jr., K. Ferdinand, M. Taylor, K. Adams, M. Sabolinski, M. Worcel, and J.N. Cohn Combination of isosorbide dinitrate and hydralazine in blacks with heart failure N EnglJ Med. 351 2004 2049 2057
117. L. Tavazzi, A.P. Maggioni, R. Marchioli, S. Barlera, M.G. Franzosi, R. Latini, D. Lucci, G.L. Nicolosi, M. Porcu, and G. Tognoni Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, doubleblind, placebo-controlled trial Lancet. 372 2008 1223 1230
118. B. Pitt, P.A. Poole-Wilson, R. Segal, F.A. Martinez, K. Dickstein, A.J. Camm, M.A. Konstam, G. Riegger, G.H. Klinger, J. Neaton, D. Sharma, and B. Thiyagarajan Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II Lancet. 355 2000 1582 1587
119. M.A. Konstam, J.D. Neaton, K. Dickstein, H. Drexler, M. Komajda, F.A. Martinez, G.A. Riegger, W. Malbecq, R.D. Smith, S. Guptha, and P.A. Poole-Wilson Effects of highdose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial Lancet. 374 2009 1840 1848
120. M.A. Pfeffer, J.J. McMurray, E.J. Velazquez, J.L. Rouleau, L. Kober, A.P. Maggioni, S.D. Solomon, K. Swedberg, F. Van de Werf, H. White, J.D. Leimberger,
121. K. Dickstein, and J. Kjekshus Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Lancet. 360 2002 752 760
122. K. Fox, I. Ford, P.G. Steg, M. Tendera, and R. Ferrari Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial Lancet. 372 2008 807 816
123. Hood WBJr, A.L. Dans, G.H. Guyatt, R. Jaeschke, and J.J. McMurray Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis J Card Fail. 10 2004 155 164
124. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354:447-55.
125. B. Rauch, R. Schiele, SchneiderS, F. Diller, N. Victor, H. Gohlke, M. Gottwik, G. Steinbeck, U. Del Castillo, R. Sack, H. Worth, H. Katus, W. Spitzer, G. Sabin, and J. Senges OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction Circulation. 122 2010 2152 2159
126. Z. Reiner, A.L. Catapano, G. De Backer, I. Graham, M.R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M.J. Chapman, R. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P.P. Filardi, G. Riccardi, R.F. Storey, D. Wood, J. Bax, A. Vahanian, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, G. Filippatos, C. Funck-Brentano, D. Hasdai, A. Hoes, R. Kearney, J. Knuuti, R. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B.A. Popescu, U. Sechtem, P.A. Sirnes, M. Tendera, A. Torbicki, P. Vardas, P. Widimsky, S. Windecker, G. Berkenboom, J. De Graaf, O. Descamps, N. Gotcheva, K. Griffith, G.F. Guida, S. Gulec, Y. Henkin, K. Huber, Y.A. Kesaniemi, J. Lekakis, A.J. Manolis, P. Marques-Vidal, L. Masana, J. McMurray, M. Mendes, Z. Pagava, T. Pedersen, E. Prescott, Q. Rato, G. Rosano, S. Sans, A. Stalenhoef, L. Tokgozoglu, M. Viigimaa, M.E. Wittekoek, and J.L. Zamorano ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J. 32 2011 1769 1818
127. J. Kjekshus, E. Apetrei, V. Barrios, M. Bohm, J.G. Cleland, J.H. Cornel, R. Dunselman, C. Fonseca, A. Goudev, R. Grande, L. Gullestad, A. Hjalmarson, J. Hradec, A. Janosi, G. Kamensky, M. Komajda, J. Korewicki, T. Kuusi, F. Mach, V. Mareev, J.J. McMurray, N. Ranjith, M. Schaufelberger, J. Vanhaecke, D.J. van Veldhuisen, F. Waagstein, H. Wedel, and J. Wikstrand Rosuvastatin in older patients with systolic heart failure N Engl J Med. 357 2007 2248 2261
128. L. Tavazzi, A.P. Maggioni, R. Marchioli, S. Barlera, M.G. Franzosi, R. Latini, D. Lucci, G.L. Nicolosi, M. Porcu, and G. Tognoni Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial Lancet. 372 2008 1231 1239
129. H. Krum, B. Massie, W.T. Abraham, K. Dickstein, L. Kober, J.J. McMurray, A. Desai, C. Gimpelewicz, A. Kandra, B. Reimund, H. Rattunde, and J. Armbrecht Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study EurJ Heart Fail. 13 2011 107 114
130. M. Gheorghiade, M. Albaghdadi, F. Zannad, G.C. Fonarow, M. Bohm, C. Gimpelewicz, J. Botha, S. Moores, E.F. Lewis, H. Rattunde, and A. Maggioni Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) EurJ Heart Fail. 13 2011 100 106
131. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S, Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski R Estol CJ, Lip GY, Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, Del Valle ML, Buchsbaum R; the WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; Published online ahead of print 2 May 2012. PubMed PMID: 22551105.
132. M. Komajda, J.J. McMurray, H. Beck-Nielsen, R. Gomis, M. Hanefeld, S.J. Pocock, P.S. Curtis, N.P. Jones, and P.D. Home Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial Eur Heart J. 31 2010 824 831
133. A.V. Hernandez, A. Usmani, A. Rajamanickam, and A. Moheet Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized 153. clinical trials AmJ Cardiovasc Drugs. 11 2011 115 128
134. E. Erdmann, B. Charbonnel, R.G. Wilcox, A.M. Skene, M. Massi-Benedetti, J. Yates, M. Tan, R. Spanheimer, E. Standl, and J.A. Dormandy Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from 154. the PROactive study (PROactive 08) Diabetes Care. 30 2007 2773 2778
135. R.E. Goldstein, S.J. Boccuzzi, D. Cruess, and S. Nattel Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem 155. Postinfarction Research Group Circulation. 83 1991 52 60
136. M. Mamdani, D.N. Juurlink, D.S. Lee, P.A. Rochon, A. Kopp, G. Naglie, P.C. Austin, A. Laupacis, and T.A. Stukel Cyclo-oxygenase-2 inhibitors versus non-selective 156. nonsteroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study Lancet. 363 2004 1751 1756
137. C. Huerta, C. Varas-Lorenzo, J. Castellsague, and L.A. Garcia Rodriguez Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in 157. the general population Heart. 92 2006 1610 1615
138. J.F. Setaro, B.L. Zaret, D.S. Schulman, H.R. Black, and R. Soufer Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling 158. and normal left ventricular systolic performance AmJ Cardiol 66 1990 981 986
139. M.J. Hung, W.J. Cherng, L.T. Kuo, and C.H. Wang Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure Int J Clin Pract. 56 2002 57 62
140. S. Yusuf, M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J. McMurray, E.L. Michelson, B. Olofsson, and J. Ostergren Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved 159 Trial. Lancet. 362 2003 777 781
141. J.G. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, and J. Taylor The perindopril in elderly people with chronic heart failure (PEP-CHF) study Eur 160. Heart J 27 2006 2338 2345
142. B.M. Massie, P.E. Carson, J.J. McMurray, M. Komajda, R. McKelvie, M.R. Zile, S. Anderson, M. Donovan, E. Iverson, C. Staiger, and A. Ptaszynska Irbesartan in patients with heart failure and preserved ejection fraction N Engl J Med. 359 2008 2456 2467
143. M.K. Chung, S.J. Szymkiewicz, M. Shao, E. Zishiri, M.J. Niebauer, B.D. Lindsay, and P.J. Tchou Aggregate national experience with the wearable cardioverterdefibrillator: event rates, compliance, and survival J Am Coll Cardiol. 56 2010 194 203
144. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos 162. G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Blanc JJ, Budaj A, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL, Smith SC Jr, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, Halperin JL, 163. Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of 164. Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the 165. European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J. 2006;27:2099-2140.
145. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med. 1997;337:1576-83. 166.
146. K.H. Kuck, R. Cappato, SiebelsJ, and R. Ruppel Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH) Circulation. 102 2000 748 754
147. S.J. Connolly, M. Gent, R.S. Roberts, R. Dorian, D. Roy, R.S. Sheldon, L.B. Mitchell, M.S. Green, G.J. Klein, and B. O'Brien Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against 167. amiodarone Circulation. 101 2000 1297 1302
148. O. Oseroff, E. Retyk, and A. Bochoeyer Subanalyses of secondary prevention implantable cardioverter-defibrillatortrials: antiarrhythmics versus implantable defibrillators 168. (AVID). Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH) Curr Opin Cardiol. 19 2004 26 30
149. A.J. Moss, W.J. Hall, D.S. Cannom, J.P. Daubert, S.L. Higgins, H. Klein, J.H. Levine, 169. Saksena, S. Waldo, A.L. Wilber, D. Brown, and M.W.M. Heo Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. 170 N Engl J Med. 335 1996 1933 1940
150. G.H. Bardy, K.L. Lee, D.B. Mark, J.E. Poole, D.L. Packer, R. Boineau, M. Domanski, C. Troutman, J. Anderson, G. Johnson, S.E. McNulty, N. Clapp-Channing, L.D. Davidson-Ray, E.S. Fraulo, D.P. Fishbein, R.M. Luceri, and J.H. Ip Amiodarone or an implantable 171. cardioverter-defibrillator for congestive heart failure N Engl J Med. 352 2005 225 237
151. S.H. Hohnloser, K.H. Kuck, R. Dorian, R.S. Roberts, J.R. Hampton, R. Hatala, E. Fain, M. Gent, and S.J. Connolly Prophylactic use of an implantable cardioverterdefibrillator after acute myocardial infarction N EnglJ Med. 351 2004 2481 2488
152. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, Kornacewicz-Jach Z, Sredniawa B, Lupkovics G, Hofgartner F, Lubinski A, Rosenqvist M, Habets A, Wegscheider K, SengesJ. Defibrillator implantation early 173. after myocardial infarction. N Engl J Med. 2009;361:1427-36.
153. A. Kadish, A. Dyer, J.P. Daubert, R. Quigg, N.A. Estes, K.P. Anderson, H. Calkins, D. Hoch, J. Goldberger, A. Shalaby, W.E. Sanders, A. Schaechter, and J.H. Levine Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy N EnglJ Med. 350 2004 2151 2158
154. G.C. Stewart, J.R. Weintraub, P.P. Pratibhu, M.J. Semigran, J.M. Camuso, K. Brooks, S.W. Tsang, M.S. Anello, V.T. Nguyen, E.F. Lewis, A. Nohria, A.S. Desai, M.M. Givertz, and L.W. Stevenson Patient expectations from implantable defibrillators to prevent death in heart failure J Card Fail. 16 2010 106 113
155. A.J. Moss, W.J. Hall, D.S. Cannom, H. Klein, M.W. Brown, J.P. Daubert, N.A. Estes, 3rd, E. Foster, H. Greenberg, S.L. Higgins, M.A. Pfeffer, S.D. Solomon, D. Wilber, and W. Zareba Cardiac-resynchronization therapy for the prevention of heart-failure events N EnglJ Med. 361 2009 1329 1338
156. A.S. Tang, G.A. Wells, M. Talajic, M.O. Arnold, R. Sheldon, S. Connolly, S.H. Hohnloser, G. Nichol, D.H. Birnie, SappJL, R. Yee, J.S. Healey, and J.L. Rouleau Cardiac-resynchronization therapy for mild-to-moderate heart failure N EnglJ Med 363 2010 2385 2395
157. M.R. Bristow, L.A. Saxon, J. Boehmer, S. Krueger, D.A. Kass, T. De Marco, R. Carson, L. DiCarlo, D. DeMets, B.G. White, D.W. DeVries, and A.M. Feldman Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure N EnglJ Med. 350 2004 2140 2150
158. J.G. Cleland, J.C. Daubert, E. Erdmann, N. Freemantle, D. Gras, L. Kappenberger, and L. Tavazzi The effect of cardiac resynchronization on morbidity and mortality in heart failure N Engl J Med. 352 2005 1539 1549
159. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski R Priori SG, Sutton R, van Veldhuisen DJ. 2010 focused update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. EurJ Heart Fail. 2010;12:1143-53.
160. J.F. Beshai, R.A. Grimm, S.F. Nagueh, J.H. Baker, S.L. 2nd Beau, S.M. Greenberg, L.A. Pires, and P.J. Tchou Cardiac-resynchronization therapy in heart failure with narrow QRS complexes N EnglJ Med. 357 2007 2461 2471
161. E.S. Chung, A.R. Leon, L. Tavazzi, J.P. Sun, R. Nihoyannopoulos, J. Merlino, W.T. Abraham, S. Ghio, C. Leclercq, J.J. Bax, C.M. Yu, J. Gorcsan 3rd, M. St John Sutton, J. De Sutter, and J. Murillo Results of the Predictors of Response to CRT (PROSPECT) trial Circulation 117 2008 2608 2616
162. C. Linde, W.T. Abraham, M.R. Gold, M. St John Sutton, S. Ghio, and C. Daubert Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms J Am Coll Cardiol 52 2008 1834 1843
163. C. Leclercq, S. Walker, C. Linde, J. Clementy, A.J. Marshall, R. Ritter, R. Djiane, R. Mabo, T. Levy, F. Gadler, C. Bailleul, and J.C. Daubert Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation Eur Heart J 23 2002 1780 1787
164. S.B. Wilton, A.A. Leung, W.A. Ghali, R. Faris, and D.V. Exner Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: a systematic review and meta-analysis Heart Rhythm 8 2011 1088 1094
165. L.F. Tops, M.J. Schalij, and J.J. Bax The effects of right ventricular apical pacing on ventricular function and dyssynchrony implications for therapy J Am Coll Cardiol 54 2009 764 776
166. P.E. Vardas, A. Auricchio, J.J. Blanc, J.C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F.B. Morgado, A. Oto, R. Sutton, and M. Trusz-Gluza Guidelines for cardiac pacing and cardiac resynchronization therapy: the Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association Eur Heart J 28 2007 2256 2295
167. A.J. Camm, R. Kirchhof, G.Y. Lip, U. Schotten, I. Savelieva, S. Ernst, I.C. Van Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, R. Colonna, R. De Caterina, J. De Sutter, A. Goette, B. Gorenek, M. Heldal, S.H. Hohloser, R. Kolh, J.Y. Le Heuzey, R. Ponikowski, and F.H. Rutten Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur HeartJ 31 2010 2369 2429
168. R.V. Lewis, J. McMurray, and D.G. McDevitt Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation J Cardiovasc Pharmacol 13 1989 1 6
169. A.U. Khand, A.C. Rankin, W. Martin, J. Taylor, I. Gemmell, and J.G. Cleland Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 42 2003 1944 1951
170. R.V. Lewis, E. Laing, T.A. Moreland, E. Service, and D.G. McDevitt A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation Eur Heart J 9 1988 279 283
171. I.C. Van Gelder, H.F. Groenveld, H.J. Crijns, Y.S. Tuininga, J.G. Tijssen, A.M. Alings, H.L. Hillege, Bergsma-KadijkJA, J.H. Cornel, O. Kamp, R. Tukkie, H.A. Bosker, D.J. Van Veldhuisen, and M.P. Van den Berg Lenient versus strict rate control in patients with atrial fibrillation N EnglJ Med 362 2010 1363 1373
172. D. Roy, M. Talajic, S. Nattel, D.G. Wyse, R. Dorian, K.L. Lee, M.G. Bourassa, J.M. Arnold, A.E. Buxton, A.J. Camm, S.J. Connolly, M. Dubuc, A. Ducharme, P.G. Guerra, S.H. Hohnloser, J. Lambert, J.Y. Le Heuzey, G. O'Hara, O.D. Pedersen, J.L. Rouleau, B.N. Singh, L.W. Stevenson, W.G. Stevenson, B. Thibault, and A.L. Waldo Rhythm control versus rate control for atrial fibrillation and heart failure N EnglJ Med 358 2008 2667 2677
173. M. Piepoli, G.Q. Villani, R. Ponikowski, A. Wright, M.D. Flather, and A.J. Coats Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure Int J Cardiol 66 1998 1 10
174. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997;350:1417-24.
175. Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO, Kautzner J, H ao S, 192. Themistoclakis S, Fanelli R, Potenza D, Massaro R, Wazni O, Schweikert R, Saliba. W, Wang R Al-Ahmad A, Beheiry S, Santarelli P, Starling RC, Dello Russo A, Pelargonio G, Brachmann J, Schibgilla V, Bonso A, Casella M, R aviele A, 193. Haissaguerre M, Natale A. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N EnglJ Med 2008;359: 1778-85.
176. M.R. MacDonald, D.T. Connelly, N.M. Hawkins, T. Steedman, J. Payne, M. Shaw, M. Denvir, S. Bhagra, S. Small, W. Martin, J.J. McMurray, and M.C. Petrie Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial Heart 97 2011 740 747
177. L. Kober, C. Torp-Pedersen, J.J. McMurray, O. Gotzsche, S. Levy, H. Crijns, J. Amlie, and J. Carlsen Increased mortality after dronedarone therapy for severe heart failure N EnglJ Med 358 2008 2678 2687
178. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum 195. A, Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacretaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbuchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsanyi J, Torp- 196. Pedersen C, Tse HF, Vardas R Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH. Dronedarone in highrisk permanent atrial fibrillation. N Engl J Med 2011;365:2268-76.
179. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg 197. D, Baker A, Friedman L, Greene HL, Huther ML, Richardson DW, the CAST Investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
180. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation Chest 137 2010 263 272
181. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial 198. fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
182. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P.A. Reilly, E. Themeles, J. Varrone, S. Wang, M. Alings, D. Xavier, J. Zhu, R. Diaz, B.S. Lewis, H. Darius, H.C. Diener, C.D. Joyner, and L. Wallentin Dabigatran versus warfarin in patients with atrial fibrillation N EnglJ Med 361 2009 1139 1151
183. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P,Jansky P, Lewis BS, Lopez-SendonJL, Pais R Parkhomenko 200. A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N EnglJ Med 2011; 365:981-92.
184. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, F ox KA, 201. Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N EnglJ Med 2011;365:883-91.
185. R.G. Hart, O. Benavente, R. McBride, and L.A. Pearce Antithrombotic therapy to prevent 202. stroke in patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 1999 492 501
186. Larson RJ, Fisher ES. Should aspirin be continued in patients started on warfarin? J Gen Intern Med 2004;19:879-86. 203.
187. Aliot EM, Stevenson WG, Almendral-Garrote JM, Bogun F, Calkins CH, Delacretaz E, Bella PD, Hindricks G, Jais P, Josephson ME, Kautzner J, Kay GN, Kuck KH, Lerman BB, Marchlinski F, Reddy V, Schalij MJ, Schilling R, Soejima K, Wilber D. EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias: 204. developed in a partnership with the European Heart Rhythm Association (EHRA), a Registered Branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society (HRS); in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA). Europace 2009;11:771-17.
188. McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, P olu KR, 205. Solomon SD, Sun Y, Swedberg K, Tendera M, van Veldhuisen DJ, Wasserman SM, Young JB. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a phase III, anaemia correction, morbiditymortality trial. Eur J Heart Fail 2009;11:795-801.
189. M. Packer, C.M. O'Connor, J.K. Ghali, M.L. Pressler, P.E. Carson, R.N. Belkin, A.B. Miller, G.W. Neuberg, D. Frid, J.H. Wertheimer, A.B. Cropp, and D.L. DeMets Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group N Engl J Med 335 1996 1107 1114
190. H.C. Wijeysundera, M.S. Hansen, E. Stanton, A.S. Cropp, C. Hall, N.S. Dhalla, J. Ghali, and J.L. Rouleau Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine Am Heart J 146 2003 291 297
191. S. Yusuf, D. Zucker, R. Peduzzi, L.D. Fisher, T. Takaro, J.W. Kennedy, K. Davis, T. Killip, E. Passamani, R. Norris, V. Mathur, E. Varnauskas, and T.C. Chalmers Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from 206. randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration Lancet 344 1994 563 570
192. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, P etrie MC, 207. O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, RouleauJL. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N EnglJ Med 2011;364:1607-16.
193. Y.J. Akashi, J. Springer, and S.D. Anker Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches Curr Heart Fail Rep 2 2005 198 203
194. T. Eschenhagen, T. Force, M.S. Ewer, G.W. de Keulenaer, T.M. Suter, S.D. Anker, M. Avkiran, E. de Azambuja, J.L. Balligand, D.L. Brutsaert, G. Condorelli, A. Hansen, S. Heymans, J.A. Hill, E. Hirsch, D. Hilfiker-Kleiner, S. Janssens, S. de Jong, G. Neubauer, B. Pieske, P. Ponikowski, M. Pirmohamed, M. Rauchhaus, D. Sawyer, P.H. Sugden, J. Wojta, F. Zannad, and A.M. Shah Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 13 2011 1 10
195. A.L. Jones, M. Barlow, P.J. Barrett-Lee, P.A. Canney, I.M. Gilmour, S.D. Robb, C.J. Plummer, A.M. Wardley, and M.W. Verrill Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring Br J Cancer 100 2009 684 692
196. H.D. Dungen, S. Apostolovic, S. Inkrot, E. Tahirovic, A. Topper, F. Mehrhof, C. Prettin, B. Putnikovic, A.N. Neskovic, M. Krotin, D. Sakac, M. Lainscak, F. Edelmann, R. Wachter, T. Rau, T. Eschenhagen, W. Doehner, S.D. Anker, F. Waagstein, C. Herrmann-Lingen, G. Gelbrich, and R. Dietz Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial Eur J Heart Fail 13 2011 670 680
197. C.M. O'Connor, W. Jiang, M. Kuchibhatla, S.G. Silva, M.S. Cuffe, D.D. Callwood, B. Zakhary, W.G. Stough, R.M. Arias, S.K. Rivelli, and R. Krishnan Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial J Am Coll Cardiol 56 2010 692 699
198. J.J. McMurray, R.R. Holman, S.M. Haffner, M.A. Bethel, B. Holzhauer, T.A. Hua, Y. Belenkov, M. Boolell, J.B. Buse, B.M. Buckley, A.R. Chacra, F.T. Chiang, B. Charbonnel, C.C. Chow, M.J. Davies, R. Deedwania, R. Diem, D. Einhorn, V. Fonseca, G.R. Fulcher, Z. Gaciong, S. Gaztambide, T. Giles, E. Horton, H. Ilkova, T. Jenssen, S.E. Kahn, H. Krum, M. Laakso, L.A. Leiter, N.S. Levitt, V. Mareev, F. Martinez, C. Masson, T. Mazzone, E. Meaney, R. Nesto, C. Pan, R. Prager, S.A. Raptis, G.E. Rutten, H. Sandstroem, F. Schaper, A. Scheen, O. Schmitz, I. Sinay, V. Soska, S. Stender, G. Tamas, G. Tognoni, J. Tuomilehto, A.S. Villamil, J. Vozar, and R.M. Califf Effect of valsartan on the incidence of diabetes and cardiovascular events N EnglJ Med 362 2010 1477 1490
199. G.L. Bakris, V. Fonseca, R.E. Katholi, J.B. McGill, F.H. Messerli, R.A. Phillips, R. Raskin, J.T. Wright, R. Oakes, M.A. Lukas, K.M. Anderson, and D.S.H. Bell for the GEMINI Investigators. Metabolic Effects of carvedilol vs metoprolol in patients with type4 2 diabetes mellitus and hypertension - a randomized contolled trial JAMA 292 2004 2227 2236
200. M.R. MacDonald, D.T. Eurich, S.R. Majumdar, J.D. Lewsey, S. Bhagra, P.S. Jhund, M.C. Petrie, J.J. McMurray, J.R. Petrie, and F.A. McAlister Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database Diabetes Care 33 2010 1213 1218
201. M. Guazzi, M. Vicenzi, R. Arena, and M.D. Guazzi PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study Circ Heart Fail 4 2011 8 17
202. J.M. Hare, B. Mangal, J. Brown, C. Fisher Jr., R. Freudenberger, W.S. Colucci, D.L. Mann, R. Liu, M.M. Givertz, and R.P. Schwarz Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study J Am Coll Cardiol 51 2008 2301 2309
203. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000;283:1967-75.
204. J.N. Cohn, M.A. Pfeffer, J. Rouleau, N. Sharpe, K. Swedberg, M. Straub, C. Wiltse, and T.J. Wright Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON) Eur J Heart Fail 5 2003 659 667
205. J.N. Cohn, S. Ziesche, R. Smith, I. Anand, W.B. Dunkman, H. Loeb, G. Cintron, W. Boden, L. Baruch, P. Rochin, and L. Loss Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group Circulation 96 1997 856 863
206. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky R Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Manolis A, Nilsson PM, Redon J, Struijker-Boudier HA, Viigimaa M, Adamopoulos S, Bertomeu V, Clement D, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, O'Brien E, Ponikowski P, Ruschitzka F, Tamargo J, van Zwieten R Waeber B, Williams B, Zamorano JL, The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536.
207. A. Dorszewski, E. Gohmann, B. Dorszewski, G.S. Werner, H. Kreuzer, and H.R. Figulla Vasodilation by urapidil in the treatment of chronic congestive heart failure in addition to angiotensin-converting enzyme inhibitors is not beneficial: results of a placebo-controlled, double-blind study J Card Fail 3 1997 91 96
208. J. Bayliss, M.S. Norell, R. Canepa-Anson, C. Reid, P. Poole-Wilson, and G. Sutton Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin Br Med J (Clin Res Ed) 290 1985 1861 1865
209. S.D. Anker, J. Comin Colet, G. Filippatos, R. Willenheimer, K. Dickstein, H. Drexler, T.F. Luscher, B. Bart, W. Banasiak, J. Niegowska, B.A. Kirwan, C. Mori, B. von Eisenhart Rothe, S.J. Pocock, P.A. Poole-Wilson, and P. Ponikowski Ferric carboxymaltose in patients with heart failure and iron deficiency N Engl J Med 361 2009 2436 2448
210. C. Ronco, P. McCullough, S.D. Anker, I. Anand, N. Aspromonte, S.M. Bagshaw, R. Bellomo, T. Berl, I. Bobek, D.N. Cruz, L. Daliento, A. Davenport, M. Haapio, H. Hillege, A.A. House, N. Katz, A. Maisel, S. Mankad, R. Zanco, A. Mebazaa, A. Palazzuoli, F. Ronco, A. Shaw, G. Sheinfeld, S. Soni, G. Vescovo, N. Zamperetti, and P. Ponikowski Acute Dialysis Quality Initiative (ADQI) consensus Group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative Eur Heart J 31 2010 703 711
211. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian R Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syva'nne M, Scholte Op, Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)*Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012, doi: 10.1093/eurheartj/ehs092. Published online ahead of print 3 May 2012.
212. R.S. McKelvie, G.W. Moe, A. Cheung, J. Costigan, A. Ducharme, E. Estrella-Holder, J.A. Ezekowitz, J. Floras, N. Giannetti, A. Grzeslo, K. Harkness, G.A. Heckman, J.G. Howlett, S. Kouz, K. Leblanc, E. Mann, E. O'Meara, M. Rajda, V. Rao, J. Simon, E. Swiggum, S. Zieroth, J.M. Arnold, T. Ashton, M. D'Astous, R. Dorian, H. Haddad, D.L. Isaac, M.H. Leblanc, R. Liu, B. Sussex, and H.J. Ross The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care Can J Cardiol 27 2011 319 338
213. T. Kasai, and T.D. Bradley Obstructive sleep apnea and heart failure: pathophysiologic and therapeutic implications J Am Coll Cardiol 57 2011 119 127
214. G.M. Felker, K.L. Lee, D.A. Bull, M.M. Redfield, L.W. Stevenson, S.R. Goldsmith, M.M. LeWinter, A. Deswal, J.L. Rouleau, E.O. Ofili, K.J. Anstrom,
215. R. Alikhan, A.T. Cohen, S. Combe, M.M. Samama, L. Desjardins, A. Eldor, C. Janbon, A. Leizorovicz, C.G. Olsson, and A.G. Turpie Prevention of venous thromboembolism in medical patients with enoxaparin: a subGroup analysis of the MEDENOX study Blood Coagul Fibrinolysis 14 2003 341 346
216. F.X. Kleber, C. Witt, G. Vogel, K. Koppenhagen, U. Schomaker, and C.W. Flosbach Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease Am Heart J 145 2003 614 621
217. U. Tebbe, S.M. Schellong, S. Haas, H.E. Gerlach, C. Abletshauser, C. Sieder, R. Bramlage, and H. Riess Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subGroup analysis of the randomized, controlled CERTIFY study Am Heart J 161 2011 322 328
218. A. Gray, S. Goodacre, D.E. Newby, M. Masson, F. Sampson, and J. Nicholl Noninvasive ventilation in acute cardiogenic pulmonary edema N Engl J Med 359 2008 142 151
219. G. Cotter, E. Metzkor, E. Kaluski, Z. Faigenberg, R. Miller, A. Simovitz, O. Shaham, D. Marghitay, M. Koren, A. Blatt, Y. Moshkovitz, R. Zaidenstein, and A. Golik Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema Lancet 351 1998 389 393
220. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40.
221. J.N. Cohn, J.A. Franciosa, G.S. Francis, D. Archibald, F. Tristani, R. Fletcher, A. Montero, G. Cintron, J. Clarke, D. Hager, R. Saunders, F. Cobb, R. Smith, H. Loeb, and H. Settle Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study N Engl J Med 306 1982 1129 1135
222. S.R. Mehta, C.P. Cannon, K.A. Fox, L. Wallentin, W.E. Boden, R. Spacek, R. Widimsky, P.A. McCullough, D. Hunt, E. Braunwald, and S. Yusuf Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials JAMA 293 2005 2908 2917
223. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994;343:311-22.
224. H.J. Dargie Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial Lancet 357 2001 1385 1390
225. J.H. Park, S. Balmain, C. Berry, J.J. Morton, and J.J. McMurray Potentially detrimental cardiovascular effects of oxygen in patients with chronic left ventricular systolic dysfunction Heart 96 2010 533 538
226. J. Rosenberg, F. Gustafsson, S. Galatius, and P.R. Hildebrandt Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature Cardiovasc Drugs Ther 19 2005 301 306
227. K.S. Channer, K.A. McLean, R. Lawson-Matthew, and M. Richardson Combination diuretic treatment in severe heart failure: a randomised controlled trial Br Heart J 71 1994 146 150
228. L.B. Tan, S. Bryant, and R.G. Murray Detrimental haemodynamic effects of cyclizine in heart failure Lancet 1 1988 560 561
229. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski R Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43.
230. R. van de Borne, R. Oren, and V.K. Somers Dopamine depresses minute ventilation in patients with heart failure Circulation 98 1998 126 131
231. M. Gheorghiade, M.A. Konstam, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, K. Swedberg, J.E. Udelson, F. Zannad, T. Cook, J. Ouyang, C. Zimmer, and C. Orlandi Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials JAMA 297 2007 1332 1343
232. K.D. Sjauw, A.E. Engstrom, M.M. Vis, R.J. van der Schaaf, J. Baan Jr., K.T. Koch, R.J. de Winter, J.J. Piek, J.G. Tijssen, and J.P. Henriques A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J 30 2009 459 468
233. M.R. Costanzo, M.T. Saltzberg, M. Jessup, J.R. Teerlink, and P.A. Sobotka Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD J Card Fail 16 2010 277 284
234. M.R. Shah, V. Hasselblad, L.W. Stevenson, C. Binanay, C.M. O'Connor, G. Sopko, and R.M. Califf Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials JAMA 294 2005 1664 1670
235. Shepperd S, McClaran J, Phillips CO, Lannin NA, Clemson LM, McCluskey A, Cameron ID, Barras SL. Discharge planning from hospital to home. Cochrane Database Syst Rev 2010;(1):CD000313.
236. C.O. Phillips, S.M. Wright, D.E. Kern, R.M. Singa, S. Shepperd, and H.R. Rubin Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis JAMA 291 2004 1358 1367
237. T.A. McDonagh, L. Blue, A.L. Clark, U. Dahlstrom, I. Ekman, M. Lainscak, K. McDonald, M. Ryder, A. Stromberg, and T. Jaarsma European Society of Cardiology Heart Failure Association Standards for delivering heart failure care Eur J Heart Fail 13 2011 235 241
238. C.W. Hamm, J.P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, R. Caso, D. Dudek, S. Gielen, K. Huber, M. Ohman, M.C. Petrie, F. Sonntag, M.S. Uva, R.F. Storey, W. Wijns, D. Zahger, J.J. Bax, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, J. Knuuti, R. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B.A. Popescu, Z. Reiner, U. Sechtem, P.A. Sirnes, A. Torbicki, A. Vahanian, S. Windecker, S. Achenbach, L. Badimon, M. Bertrand, H.E. Botker, J.P. Collet, F. Crea, N. Danchin, E. Falk, J. Goudevenos, D. Gulba, R. Hambrecht, J. Herrmann, A. Kastrati, K. Kjeldsen, S.D. Kristensen, R. Lancellotti, J. Mehilli, B. Merkely, G. Montalescot, F.J. Neumann, L. Neyses, PerkJ, M. Roffi, F. Romeo, M. Ruda, E. Swahn, M. Valgimigli, C.J. Vrints, and P. Widimsky ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
239. F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, A. Kastrati, A. Rosengren, P.G. Steg, M. Tubaro, F. Verheugt, F. Weidinger, and M. Weis Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology Eur Heart J 29 2008 2909 2945
240. A. Torbicki, A. Perrier, S. Konstantinides, G. Agnelli, N. Galie, R. Pruszczyk, F. Bengel, A.J. Brady, D. Ferreira, U. Janssens, W. Klepetko, E. Mayer, M. Remy-Jardin, and J.P. Bassand Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur HeartJ 29 2008 2276 2315
241. N. Galie, M.M. Hoeper, M. Humbert, A. Torbicki, VachieryJL, J.A. Barbera, M. Beghetti, R. Corris, S. Gaine, J.S. Gibbs, M.A. Gomez-Sanchez, G. Jondeau, W. Klepetko, C. Opitz, A. Peacock, L. Rubin, M. Zellweger, and G. Simonneau Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
242. A. Mebazaa, A.A. Pitsis, A. Rudiger, TollerW, D. Longrois, S.E. Ricksten, I. Bobek, S. De Hert, G. Wieselthaler, U. Schirmer, L.K. von Segesser, M. Sander, D. Poldermans, M. Ranucci, P.C. Karpati, R. Wouters, M. Seeberger, E.R. Schmid, W. Weder, and F. Follath Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery Crit Care 14 2010 201
243. K. Sliwa, D. Hilfiker-Kleiner, M.C. Petrie, A. Mebazaa, B. Pieske, E. Buchmann, V. Regitz-Zagrosek, M. Schaufelberger, L. Tavazzi, D.J. van Veldhuisen, H. Watkins, A.J. Shah, P.M. Seferovic, U. Elkayam, S. Pankuweit, Z. Papp, F. Mouquet, and J.J. McMurray Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy EurJ Heart Fail 12 2010 767 778
244. European Society of Gynecology; Association for European Paediatric Cardiology; German Society for Gender Medicine; Authors/Task Force Members, Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, Gibbs JS, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M, Maas AH, Morais J, Nihoyannopoulos P, Pieper PG, Presbitero P, Roos-Hesselink JW, Schaufelberger M, Seeland U, Torracca L; ESC Committee for Practice Guidelines, Bax J, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Baumgartner H, Deaton C, Aguiar C, Al-Attar N, Garcia AA, Antoniou A, Coman I, Elkayam U, Gomez-Sanchez MA, Gotcheva N, Hilfiker-Kleiner D, Kiss RG, Kitsiou A, Konings KT, Lip GY, Manolis A, Mebaaza A, Mintale I, Morice MC, Mulder BJ, Pasquet A, Price S, Priori SG, Salvador MJ, Shotan A, Silversides CK, Skouby SO, Stein JI, Tornos R Vejlstrup N, Walker F, Warnes C. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011;32:3147-97.
245. G.P. Diller, K. Dimopoulos, D. Okonko, W. Li, S.V. Babu-Narayan, C.S. Broberg, B. Johansson, B. Bouzas, M.J. Mullen, P.A. Poole-Wilson, D.P. Francis, and M.A. Gatzoulis Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication Circulation 112 2005 828 835
246. H. Baumgartner, R. Bonhoeffer, N.M. De Groot, F. de Haan, J.E. Deanfield, N. Galie, M.A. Gatzoulis, C. Gohlke-Baerwolf, H. Kaemmerer, R. Kilner, F. Meijboom, B.J. Mulder, E. Oechslin, J.M. Oliver, A. Serraf, A. Szatmari, E. Thaulow, P.R. Vouhe, and E. Walma ESC Guidelines for the management of grown-up congenital heart disease (new version 2010) Eur Heart J 31 2010 2915 2957
247. R.H. Jones, E.J. Velazquez, R.E. Michler, G. Sopko, J.K. Oh, C.M. O'Connor, J.A. Hill, L. Menicanti, Z. Sadowski, P. Desvigne-Nickens, J.L. Rouleau, and K.L. Lee Coronary bypass surgery with or without surgical ventricular reconstruction N Engl J Med 360 2009 1705 1717
248. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baro' n-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B, Lancellotti R Pierard L, Price S, Schaefers H-J, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M. Guidelines on the Management of Valvular Heart Disease (Version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur HeartJ 2012, doi:10.1093/eurheartj/ehs109. in press.
249. C.R. Smith, M.B. Leon, M.J. Mack, D.C. Miller, J.W. Moses, L.G. Svensson, E.M. Tuzcu, J.G. Webb, G.P. Fontana, R.R. Makkar, M. Williams, T. Dewey, S. Kapadia, V. Babaliaros, V.H. Thourani, P. Corso, A.D. Pichard, J.E. Bavaria, H.C. Herrmann, J.J. Akin, W.N. Anderson, D. Wang, and S.J. Pocock Transcatheter versus surgical aorticvalve replacement in high-risk patients N EnglJ Med 364 2011 2187 2198
250. C.R. Smith, M.B. Leon, M.J. Mack, C. Miller, J.W. Moses, L.G. Svensson, M. Tuzcu, J.G. Webb, G.P. Fontana, R.R. Makkar, M. WIlliams, T. Dewey, S. Kapadia, V. Babaliaros, V.H. Thourani, P. Corso, A.D. Pichard, J.E. Bavaria, H.C. Herrmann, J. Akin, W.N. Anderson, D. Wang, and S.J. Pocock for the PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients N Eng J Med 364 2011 2187 2198
251. T. Feldman, S. Kar, M. Rinaldi, R. Fail, J. Hermiller, R. Smalling, P.L. Whitlow, W. Gray, R. Low, H.C. Herrmann, S. Lim, E. Foster, and D. Glower Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort J Am Coll Cardiol 54 2009 686 694
252. N.R. Banner, R.S. Bonser, A.L. Clark, S. Clark, P.J. Cowburn, R.S. Gardner, P.R. Kalra, T. McDonagh, C.A. Rogers, L. Swan, J. Parameshwar, H.L. Thomas, and S.G. Williams UK guidelines for referral and assessment of adults for heart transplantation Heart 97 2011 1520 1527
253. M.R. Mehra, J. Kobashigawa, R. Starling, S. Russell, P.A. Uber, J. Parameshwar, R. Mohacsi, S. Augustine, K. Aaronson, and M. Barr Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates-2006 J Heart Lung Transplant 25 2006 1024 1042
254. K.B. Shah, D.G. Tang, R.H. Cooke, S. Harton, M. Flattery, G.J. Katlaps, V. Kasirajan, and M.L. Hess Implantable mechanical circulatory support: demystifying patients with ventricular assist devices and artificial hearts Clin Cardiol 34 2011 147 152
255. E.A. Rose, A.C. Gelijns, A.J. Moskowitz, D.F. Heitjan, L.W. Stevenson, W. Dembitsky, J.W. Long, D.D. Ascheim, A.R. Tierney, R.G. Levitan, J.T. Watson, P. Meier, N.S. Ronan, P.A. Shapiro, R.M. Lazar, L.W. Miller, L. Gupta, O.H. Frazier, P. Desvigne-Nickens, M.C. Oz, and V.L. Poirier Long-term use of a left ventricular assist device for end-stage heart failure N EnglJ Med 345 2001 1435 1443
256. M.S. Slaughter, J.G. Rogers, C.A. Milano, S.D. Russell, J.V. Conte, D. Feldman, B. Sun, A.J. Tatooles, R.M. Delgado 3rd, J.W. Long, T.C. Wozniak, W. Ghumman, D.J. Farrar, and O.H. Frazier Advanced heart failure treated with continuous-flow left ventricular assist device N EnglJ Med 361 2009 2241 2251
257. E.J. Birks, P.D. Tansley, J. Hardy, R.S. George, C.T. Bowles, M. Burke, N.R. Banner, A. Khaghani, and M.H. Yacoub Left ventricular assist device and drug therapy for the reversal of heart failure N EnglJ Med 355 2006 1873 1884
258. P. Khazanie, and J.G. Rogers Patient selection for left ventricular assist devices Congest Heart Fail 17 2011 227 234
259. F.D. Pagani, L.W. Miller, S.D. Russell, K.D. Aaronson, R. John, A.J. Boyle, J.V. Conte, R.C. Bogaev, T.E. MacGillivray, Y. Naka, D. Mancini, H.T. Massey, L. Chen, C.T. Klodell, J.M. Aranda, N. Moazami, G.A. Ewald, D.J. Farrar, and O.H. Frazier Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device J Am Coll Cardiol 54 2009 312 321
260. M. Lainscak, L. Blue, A.L. Clark, U. Dahlstrom, K. Dickstein, I. Ekman, T. McDonagh, McMurrayJJ, M. Ryder, S. Stewart, A. Stromberg, and T. Jaarsma Self-care management of heart failure: practical recommendations from the Patient Care Committee of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 13 2011 115 126
261. S. Paterna, R. Gaspare, S. Fasullo, F.M. Sarullo, and P. Di Pasquale Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin Sci (Lond) 114 2008 221 230
262. L.H. Powell, J.E. Calvin Jr., D. Richardson, I. Janssen, C.F. Mendes de Leon, K.J. Flynn, K.L. Grady, C.S. Rucker-Whitaker, C. Eaton, and E. Avery Self-management counseling in patients with heart failure: the heart failure adherence and retention randomized behavioral trial JAMA 304 2010 1331 1338
263. C.M. O'Connor, D.J. Whellan, K.L. Lee, S.J. Keteyian, L.S. Cooper, S.J. Ellis, E.S. Leifer, W.E. Kraus, D.W. Kitzman, J.A. Blumenthal, D.S. Rendall, N.H. Miller, J.L. Fleg, K.A. Schulman, R.S. McKelvie, F. Zannad, and I.L. Piña HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HFACTION randomized controlled trial JAMA 301 2009 1439 1450
264. M.F. Piepoli, V. Conraads, U. Corra, K. Dickstein, D.P. Francis, T. Jaarsma, J. McMurray, B. Pieske, E. Piotrowicz, J.P. Schmid, S.D. Anker, A.C. Solal, G.S. Filippatos, A.W. Hoes, S. Gielen, P. Giannuzzi, and P.P. Ponikowski Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation Eur J Heart Fail 13 2011 347 357
265. J. Sochalski, T. Jaarsma, H.M. Krumholz, A. Laramee, J.J. McMurray, M.D. Naylor, M.W. Rich, B. Riegel, and S. Stewart What works in chronic care management: the case of heart failure Health Aff 28 2009 179 189
266. P. Porapakkham, H. Zimmet, B. Billah, and H. Krum B-type natriuretic peptide-guided heart failure therapy: a meta-analysis Arch Intern Med 170 2010 507 514
267. D.J. van Veldhuisen, F. Braunschweig, V. Conraads, I. Ford, M.R. Cowie, G. Jondeau, J. Kautzner, R.M. Aguilera, M. Lunati, B. Gerritse, and M. Borggrefe Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure Circulation 124 2011 1719 1726
268. W.T. Abraham, P.B. Adamson, R.C. Bourge, M.F. Aaron, M.R. Costanzo, L.W. Stevenson, W. Strickland, S. Neelagaru, N. Raval, S. Krueger, S. Weiner, D. Shavelle, B. Jeffries, and J.S. Yadav Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial Lancet 377 2011 658 666
269. S.D. Anker, F. Koehler, and W.T. Abraham Telemedicine and remote management of patients with heart failure Lancet 378 2011 731 739
270. S.C. Inglis, R.A. Clark, F.A. McAlister, S. Stewart, and J.G. Cleland Which components of heart failure programmes are effective?. A systematic review and meta-analysis of the outcomes of structured telephone support or telemonitoring as the primary component of chronic heart failure management in 8323 patients: Abridged Cochrane Review Eur J Heart Fail 13 2011 1028 1040
271. T. Jaarsma, J.M. Beattie, M. Ryder, F.H. Rutten, T. McDonagh, R. Mohacsi, S.A. Murray, T. Grodzicki, I. Bergh, M. Metra, I. Ekman, C. Angermann, M. Leventhal, A. Pitsis, S.D. Anker, A. Gavazzi, R. Ponikowski, K. Dickstein, E. Delacretaz, L. Blue, F. Strasser, and J. McMurray Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology EurJ Heart Fail 11 2009 433 443